DK3529248T3
(en )
2020-09-14
Pharmaceutical compositions
BR112016030368A2
(en )
2018-07-17
ophthalmic composition
DK3160956T3
(en )
2020-08-31
Inhibitors of lysine-specific demethylase-1
DK3102576T3
(en )
2019-07-22
DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA
DK3089741T3
(en )
2021-06-07
PHARMACEUTICAL COMPOSITIONS INCLUDING AZD9291
DK3511319T3
(en )
2023-07-31
INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE-1
BR112016026879A2
(en )
2017-08-15
LIQUID PHARMACEUTICAL COMPOSITION
DK3116491T3
(en )
2021-08-09
PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC ACTIVE COMPOUNDS
DK2968221T3
(en )
2019-08-05
PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE
BR112017000042A2
(en )
2018-07-17
lysine-specific demethylase-1 inhibitors
DK3116475T3
(en )
2020-12-07
DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS
DK3283210T3
(en )
2021-11-22
COURSE OF ACTION
DK3199161T3
(en )
2022-01-03
Pharmaceutical preparation
DK3331498T3
(en )
2020-06-15
NATIONAL COMPOSITION
DK3191085T3
(en )
2021-06-28
ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS
ES2717715T3
(en )
2019-06-24
Pharmaceutical composition comprising polymorph IV of ivabradine hydrochloride
DK3313370T3
(en )
2021-03-29
Ophthalmological pharmaceutical composition
FR3024647B1
(en )
2017-02-17
TRANSAT OF PUERICULTURE
DK3256138T3
(en )
2022-05-16
PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM
DK3288967T3
(en )
2020-02-10
PHARMACEUTICAL RELATIONSHIP
DK3285588T3
(en )
2019-07-08
COURSE OF ACTION
DK3089740T3
(en )
2020-08-03
PHARMACEUTICAL COMPOSITION
DK3453388T3
(en )
2023-04-24
Pharmaceutical solution comprising dopamine hydrochloride
TH1501005346A
(en )
2018-11-01
Pharmaceutical composition of S-ketamine hydrochloride
DK3558261T3
(en )
2022-06-20
PHARMACEUTICAL COMPOSITIONS INCLUDING SAFINAMIDE